HK1206558A1 - Compositions, formulations and methods for treating ocular diseases - Google Patents
Compositions, formulations and methods for treating ocular diseasesInfo
- Publication number
- HK1206558A1 HK1206558A1 HK15107185.3A HK15107185A HK1206558A1 HK 1206558 A1 HK1206558 A1 HK 1206558A1 HK 15107185 A HK15107185 A HK 15107185A HK 1206558 A1 HK1206558 A1 HK 1206558A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulations
- compositions
- methods
- ocular diseases
- treating ocular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 208000022873 Ocular disease Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792868P | 2013-03-15 | 2013-03-15 | |
US201361792679P | 2013-03-15 | 2013-03-15 | |
US201361882056P | 2013-09-25 | 2013-09-25 | |
US201361882048P | 2013-09-25 | 2013-09-25 | |
US201461934570P | 2014-01-31 | 2014-01-31 | |
PCT/US2014/029723 WO2014145068A1 (fr) | 2013-03-15 | 2014-03-14 | Compositions, formulations et méthodes de traitement de maladies oculaires |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206558A1 true HK1206558A1 (en) | 2016-01-15 |
Family
ID=51529957
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107185.3A HK1206558A1 (en) | 2013-03-15 | 2015-07-27 | Compositions, formulations and methods for treating ocular diseases |
HK16108038.9A HK1219836A1 (zh) | 2013-03-15 | 2016-07-11 | 用於治療眼病的組合物、製劑和方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16108038.9A HK1219836A1 (zh) | 2013-03-15 | 2016-07-11 | 用於治療眼病的組合物、製劑和方法 |
Country Status (17)
Country | Link |
---|---|
US (10) | US9440963B2 (fr) |
EP (3) | EP2967066B1 (fr) |
JP (3) | JP6572201B2 (fr) |
KR (1) | KR20150129019A (fr) |
CN (2) | CN109925312A (fr) |
AU (2) | AU2014233363B2 (fr) |
BR (1) | BR112015023753A2 (fr) |
CA (1) | CA2903871A1 (fr) |
ES (2) | ES2766326T3 (fr) |
GB (3) | GB2516561B (fr) |
HK (2) | HK1206558A1 (fr) |
IL (2) | IL240786B (fr) |
MX (1) | MX371382B (fr) |
MY (1) | MY171945A (fr) |
PH (2) | PH12015502153B1 (fr) |
SG (1) | SG11201507131WA (fr) |
WO (1) | WO2014145068A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
AU2010271105C1 (en) | 2009-01-12 | 2014-08-21 | Aerpio Therapeutics, Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
CN102933207B (zh) | 2009-10-30 | 2018-02-02 | Ix生物医药有限公司 | 快速溶解固体剂型 |
CA2774039A1 (fr) | 2009-11-06 | 2011-05-12 | Aerpio Therapeutics Inc. | Procedes pour augmenter la stabilisation du facteur inductible par l'hypoxie 1-alpha |
US20180092883A1 (en) * | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
ES2748519T3 (es) | 2010-12-08 | 2020-03-17 | Convatec Technologies Inc | Accesorio de sistema de exudado de heridas |
US10207031B2 (en) | 2010-12-08 | 2019-02-19 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
EP2766044B1 (fr) | 2011-10-13 | 2019-12-11 | Aerpio Therapeutics, Inc. | Traitement de maladies oculaires |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
CN107669649A (zh) * | 2012-10-11 | 2018-02-09 | Ix生物制药有限公司 | 固体剂型 |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
WO2014145068A1 (fr) * | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations et méthodes de traitement de maladies oculaires |
US9388135B2 (en) | 2014-02-19 | 2016-07-12 | Aerpio Therapeutics, Inc. | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
WO2016022813A1 (fr) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combinaison d'immunothérapies avec des activateurs de tie -2 |
KR20180054677A (ko) | 2015-09-23 | 2018-05-24 | 에르피오 세러퓨틱스 인코포레이티드 | Tie-2의 활성화제로 안내압을 치료하는 방법 |
EP3364674B1 (fr) * | 2015-11-06 | 2019-10-09 | Huawei Technologies Co., Ltd. | Procédé d'itinérance vocale, élément de réseau de gestion de mobilité, et élément de réseau d'accès |
SG10201912556VA (en) | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
CN109996440A (zh) * | 2016-10-21 | 2019-07-09 | 曼宁研究有限公司 | Ve-ptp敲除 |
WO2020068653A1 (fr) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | ANTICORPS MULTISPÉCIFIQUES CIBLANT HPTP- β (VE-PTP) ET VEGF |
CN114072205A (zh) * | 2019-04-18 | 2022-02-18 | 视点制药公司 | 用tie-2激活剂治疗高血压的方法 |
CA3138682A1 (fr) * | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Activateurs de tie -2 ciblant le canal de schlemm |
GB2589400A (en) * | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
EP4051267A4 (fr) | 2019-10-29 | 2023-12-06 | EyePoint Pharmaceuticals, Inc. | Activateurs à petites molécules de tie-2 |
JP2023530457A (ja) * | 2020-06-16 | 2023-07-18 | リプカ,エイミー | 小分子ve-ptp阻害剤 |
WO2022133232A1 (fr) * | 2020-12-18 | 2022-06-23 | EyePoint Pharmaceuticals, Inc. | Procédés de fabrication d'activateurs à petites molécules de tie -2 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5078486A (en) | 1989-10-13 | 1992-01-07 | Evans David W | Self-calibrating vision test apparatus |
US5688781A (en) | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
EP0821728B1 (fr) | 1995-04-06 | 2004-08-11 | Regeneron Pharmaceuticals, Inc. | Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations |
US6455031B1 (en) * | 1997-06-18 | 2002-09-24 | David G Davies | Methods and compositions for controlling biofilm development |
US6455035B1 (en) * | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
EP1350792A1 (fr) * | 2000-12-11 | 2003-10-08 | Takeda Chemical Industries, Ltd. | Composition medicinale dont la solubilite dans l'eau est amelioree |
SE518981C2 (sv) | 2000-12-14 | 2002-12-17 | Shl Medical Ab | Autoinjektor |
US7166435B2 (en) * | 2001-08-06 | 2007-01-23 | The Quigley Corporation | Compositions and methods for reducing the transmissivity of illnesses |
US20030158199A1 (en) * | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
CA2483449A1 (fr) | 2002-04-25 | 2003-11-06 | University Of Connecticut Health Center | Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7091193B2 (en) * | 2002-10-09 | 2006-08-15 | Kosan Biosciences Incorporated | Therapeutic formulations |
US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
AU2003292838A1 (en) * | 2002-12-27 | 2004-07-29 | Kirin Beer Kabushiki Kaisha | Therapeutic agent for wet age-related macular degeneration |
CA2520255C (fr) * | 2003-04-09 | 2014-07-08 | Exelixis, Inc. | Modulateurs de tie-2 et procedes d'utilisation |
KR20060006975A (ko) * | 2003-05-30 | 2006-01-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
JP2008509085A (ja) * | 2004-06-02 | 2008-03-27 | バルティオン テクニリーネン トゥトキムスケスクス | T細胞タンパク質チロシンホスファターゼの活性化方法およびそれに基づく治療方法 |
NZ570381A (en) * | 2006-02-09 | 2011-02-25 | Daiichi Sankyo Co Ltd | Anti-cancer pharmaceutical composition |
KR101482483B1 (ko) * | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
WO2008027013A2 (fr) * | 2006-08-29 | 2008-03-06 | National Cancer Centre | Composition et procédé |
DK2076290T3 (en) * | 2006-10-27 | 2017-01-23 | Sunnybrook Health Sciences Center | MULTIMERIC TIE 2 AGONISTS AND APPLICATIONS THEREOF IN STIMULATING ANGIOGENESIS |
ATE514443T1 (de) | 2006-12-13 | 2011-07-15 | Shl Group Ab | Autoinjektor |
DK2131898T3 (en) | 2007-03-23 | 2017-10-16 | Shl Group Ab | autoinjector |
US8277412B2 (en) | 2007-07-06 | 2012-10-02 | Shl Group Ab | One shot injector with dual springs |
US8038649B2 (en) | 2007-09-18 | 2011-10-18 | Shl Group Ab | Automatic injection device with needle insertion |
CN101980716B (zh) * | 2008-03-31 | 2012-11-21 | 株式会社资生堂 | 血管成熟化、正常化或稳定化剂以及皱纹防止和/或改善剂 |
ES2637346T3 (es) | 2008-05-20 | 2017-10-11 | Shl Group Ab | Dispositivo de administración de medicamentos con un amortiguador |
US8075517B2 (en) | 2008-06-11 | 2011-12-13 | Shl Group Ab | Medicament delivery device |
EP2319537B1 (fr) * | 2008-06-18 | 2015-04-29 | Shiseido Company, Ltd. | Stabilisateur de vaisseau lymphatique |
JP4751482B2 (ja) * | 2008-07-22 | 2011-08-17 | 株式会社メニコン | コンタクトレンズ用液剤 |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
AU2010271105C1 (en) | 2009-01-12 | 2014-08-21 | Aerpio Therapeutics, Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
WO2010081172A1 (fr) * | 2009-01-12 | 2010-07-15 | Akebia Therapeutics Inc. | Méthodes de traitement du syndrome de fuite vasculaire |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
TWI393578B (zh) | 2009-07-07 | 2013-04-21 | Shl Group Ab | 注射裝置 |
TW201105363A (en) * | 2009-07-14 | 2011-02-16 | Univ Yamagata | Eye drop for macular edema treatment |
CA2774039A1 (fr) | 2009-11-06 | 2011-05-12 | Aerpio Therapeutics Inc. | Procedes pour augmenter la stabilisation du facteur inductible par l'hypoxie 1-alpha |
JP2011201811A (ja) * | 2010-03-25 | 2011-10-13 | Shiseido Co Ltd | Tie2活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 |
US20110319455A1 (en) | 2010-04-19 | 2011-12-29 | Bruce Steven Klein | Antifungal Treatment |
CA2797247C (fr) * | 2010-04-28 | 2019-10-22 | Sunnybrook Health Sciences Centre | Procedes et utilisations d'agents de liaison a tie2 et/ou d'agents d'activation de tie2 |
RU2600794C2 (ru) | 2010-10-07 | 2016-10-27 | Аэрпио Терапьютикс, Инк. | Композиции и способы лечения глазного отека, неоваскуляризации и связанных с ними заболеваний |
EP2647385A4 (fr) * | 2010-12-02 | 2014-04-30 | Maruzen Pharm Co Ltd | ACTIVATEUR DE Tie2, INHIBITEUR DU FACTEUR DE CROISSANCE VASCULAIRE ENDOTHÉLIAL (VEGF), AGENT ANTI-ANGIOGÉNIQUE, AGENT POUR LA MATURATION DES VAISSEAUX SANGUINS, AGENT POUR LA NORMALISATION DES VAISSEAUX SANGUINS, AGENT POUR LA STABILISATION DES VAISSEAUX SANGUINS, ET COMPOSITION PHARMACEUTIQUE |
CN102532042A (zh) * | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
JP2014508749A (ja) * | 2011-02-11 | 2014-04-10 | サイヴィーダ ユーエス,インコーポレイテッド | 抗浮腫治療薬を使用する黄斑浮腫の治療方法 |
EP2766044B1 (fr) | 2011-10-13 | 2019-12-11 | Aerpio Therapeutics, Inc. | Traitement de maladies oculaires |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
US20150050277A1 (en) * | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
WO2014145068A1 (fr) * | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations et méthodes de traitement de maladies oculaires |
US9388135B2 (en) | 2014-02-19 | 2016-07-12 | Aerpio Therapeutics, Inc. | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
US9719135B2 (en) * | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
-
2014
- 2014-03-14 WO PCT/US2014/029723 patent/WO2014145068A1/fr active Application Filing
- 2014-03-14 GB GB1411935.8A patent/GB2516561B/en active Active
- 2014-03-14 JP JP2016503207A patent/JP6572201B2/ja active Active
- 2014-03-14 SG SG11201507131WA patent/SG11201507131WA/en unknown
- 2014-03-14 EP EP14762974.5A patent/EP2967066B1/fr active Active
- 2014-03-14 GB GB1520656.8A patent/GB2540638B/en active Active
- 2014-03-14 BR BR112015023753A patent/BR112015023753A2/pt not_active Application Discontinuation
- 2014-03-14 CN CN201910221542.4A patent/CN109925312A/zh active Pending
- 2014-03-14 MX MX2015011131A patent/MX371382B/es active IP Right Grant
- 2014-03-14 US US13/999,670 patent/US9440963B2/en active Active
- 2014-03-14 CN CN201480028572.9A patent/CN105307498B/zh active Active
- 2014-03-14 GB GB1709419.4A patent/GB2549865B/en active Active
- 2014-03-14 CA CA2903871A patent/CA2903871A1/fr not_active Abandoned
- 2014-03-14 ES ES14762974T patent/ES2766326T3/es active Active
- 2014-03-14 EP EP19174479.6A patent/EP3607821B1/fr active Active
- 2014-03-14 ES ES19174479T patent/ES2928162T3/es active Active
- 2014-03-14 EP EP22171032.0A patent/EP4101297A1/fr active Pending
- 2014-03-14 MY MYPI2015002288A patent/MY171945A/en unknown
- 2014-03-14 AU AU2014233363A patent/AU2014233363B2/en active Active
- 2014-03-14 KR KR1020157029411A patent/KR20150129019A/ko not_active Application Discontinuation
-
2015
- 2015-07-27 HK HK15107185.3A patent/HK1206558A1/xx unknown
- 2015-08-24 IL IL240786A patent/IL240786B/en active IP Right Grant
- 2015-09-15 PH PH12015502153A patent/PH12015502153B1/en unknown
-
2016
- 2016-04-14 US US15/099,161 patent/US20160220541A1/en not_active Abandoned
- 2016-04-14 US US15/098,955 patent/US20160220540A1/en not_active Abandoned
- 2016-07-11 HK HK16108038.9A patent/HK1219836A1/zh unknown
-
2017
- 2017-02-27 US US15/443,622 patent/US20180022741A1/en not_active Abandoned
- 2017-09-28 AU AU2017235953A patent/AU2017235953B2/en not_active Expired - Fee Related
-
2018
- 2018-04-20 US US15/958,355 patent/US20180237430A1/en not_active Abandoned
- 2018-04-20 US US15/958,358 patent/US20180237431A1/en not_active Abandoned
- 2018-04-20 US US15/958,346 patent/US20180237429A1/en not_active Abandoned
- 2018-05-02 US US15/969,109 patent/US20180251457A1/en not_active Abandoned
-
2019
- 2019-07-11 IL IL267997A patent/IL267997A/en unknown
- 2019-08-09 JP JP2019147238A patent/JP6865254B2/ja active Active
- 2019-09-04 PH PH12019502018A patent/PH12019502018A1/en unknown
-
2020
- 2020-05-29 US US16/888,247 patent/US20200361926A1/en not_active Abandoned
-
2021
- 2021-04-05 JP JP2021064106A patent/JP7249374B2/ja active Active
-
2022
- 2022-03-03 US US17/685,802 patent/US20220274976A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
HK1225305A1 (zh) | 治療腦疾病的方法和組合物 | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
EP2991649A4 (fr) | Compositions et procédés de traitement d'états et de maladies psychiques liés au microbiote | |
HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
HK1220418A1 (zh) | 治療呼吸系統疾病的方法及為此而製的製劑 | |
EP3068905A4 (fr) | Méthodes et compositions pour traiter la maladie de huntington | |
ZA201505390B (en) | Compositions and methods for treating pests | |
EP2958936A4 (fr) | Méthodes et compositions pour le traitement de la maladie de forbes-cori | |
DK3292875T3 (en) | Compositions and methods for treating diseases | |
EP3139928A4 (fr) | Compositions d'anordrine et méthodes de traitement de maladies | |
EP3110446A4 (fr) | Procédés et compositions pour le traitement de maladies associées à siglec-8 | |
EP3086809A4 (fr) | Compositions et procédés de traitement de troubles oculaires | |
EP3240577A4 (fr) | Procédés et compositions de traitement de maladies cérébrales | |
AU2014306716B2 (en) | Compositions and methods for treating celiac sprue disease | |
SG10201710538XA (en) | Compositions and methods for treating skin | |
EP2968452A4 (fr) | Compositions et procédés pour traiter une maladie rétinienne | |
EP3265103A4 (fr) | Compositions et méthodes de traitement de maladies oculaires | |
EP2968505A4 (fr) | Compositions et procédés destinés au traitement de maladies auto-immunes | |
EP2988737A4 (fr) | Procédés et compositions pour le traitement de maladies | |
EP2994156A4 (fr) | Composés, compositions et procédés permettant le traitement des maladies par inhibition de l'activité de tgf- | |
AU2013903871A0 (en) | Compositions for treating skin conditions |